Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | WDR5 | P61964 | 3/20 | 0.44 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.40 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10578851 | 0.84 | BRS3 (0.74) | BRS3KMT2AWDR5SHMT2SMN1; SMN2 | |
| Ufiprazole SCHEMBL7950477 | 0.83 | BRS3 (0.82) | BRS3KMT2AWDR5SMN1; SMN2CYP2C9 | |
| Ufiprazole SCHEMBL662986 | 0.82 | BRS3 (0.84) | BRS3KMT2AWDR5SMN1; SMN2CYP2C9 | |
| Ufiprazole SCHEMBL29455226 | 0.82 | BRS3 (0.84) | BRS3KMT2AWDR5SMN1; SMN2CYP2C9 | |
| SCHEMBL7851296 | 0.81 | BRS3 (0.69) | BRS3KMT2AWDR5SHMT2SMN1; SMN2 | |
| Ufiprazole SCHEMBL7929368 | 0.81 | BRS3 (0.82) | BRS3KMT2AWDR5SMN1; SMN2CYP2C9 | |
| Ufiprazole SCHEMBL31529606 | 0.81 | BRS3 (0.82) | BRS3KMT2AWDR5SMN1; SMN2CYP2C9 | |
| SCHEMBL10715411 | 0.80 | BRS3 (0.68) | BRS3KMT2AWDR5SHMT2SMN1; SMN2 | |
| Ufiprazole SCHEMBL1816535 | 0.80 | BRS3 (1.00) | BRS3KMT2AWDR5SMN1; SMN2CYP2C9 | |
| Ufiprazole SCHEMBL29693729 | 0.80 | BRS3 (1.00) | BRS3KMT2AWDR5SMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289425-A2 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | Tseng, Yufeng, Jane (US) | 2023-12-13 | — | — | EP | claimed |
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | YODA THERAPEUTICS INC. (TW) | 2023-01-19 | — | — | US | claimed |
| EP-4108240-A2 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | Yoda Pharmaceuticals Inc. (KY) | 2022-12-28 | — | — | EP | claimed |
| US-20200361894-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | NATIONAL YANG MING CHIAO TUNG UNIVERSITY (TW) | 2020-11-19 | — | — | US | claimed |
| EP-3512840-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | Tseng, Yufeng, Jane (US) | 2019-07-24 | — | — | EP | claimed |
| WO-2018053161-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | NATIONAL TAIWAN UNIVERSITY (TW) | 2018-03-22 | — | — | WO | claimed |
| EP-3512840-B1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | TSENG YUFENG JANE (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4289425-A2 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | Tseng, Yufeng, Jane (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | YODA THERAPEUTICS INC. (TW) | 2023-01-19 | — | — | US | disclosed |
| EP-4108240-A2 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | Yoda Pharmaceuticals Inc. (KY) | 2022-12-28 | — | — | EP | disclosed |
| US-11370775-B2 | Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors | Tseng, Yufeng Jane (US) | 2022-06-28 | — | — | US | disclosed |
| US-20200361894-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | NATIONAL YANG MING CHIAO TUNG UNIVERSITY (TW) | 2020-11-19 | — | — | US | disclosed |
| EP-3512840-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | Tseng, Yufeng, Jane (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018053161-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | NATIONAL TAIWAN UNIVERSITY (TW) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | NLRP3, NOD1, NLRP1 | BRS3 2058/4885KMT2A 4102/4885WDR5 958/4885 |
| US-11370775-B2 | Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors | DAO, DDO, IL4I1 | BRS3 2817/4885KMT2A 1384/4885WDR5 1751/4885 |
| US-20200361894-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | DAO, DDO, DDC | BRS3 2789/4885KMT2A 943/4885WDR5 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.